Frank Rimerman Advisors’s Royalty Pharma RPRX Stock Holding History

Frank Rimerman Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$503K	Hold	10,493	–	–	0.03%	375
2025 Q4	$405K	Sell	10,493 -19	-0.2%	-$725	0.03%	431
2025 Q3	$371K	Buy	10,512 +57	+0.5%	+$2.06K	0.02%	430
2025 Q2	$377K	Buy	10,455 +3,863	+59%	+$128K	0.03%	399
2025 Q1	$205K	Buy	+6,592	New	+$209K	0.02%	496

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frank Rimerman Advisors's RPRX Position: Q1 2026 in Review

Frank Rimerman Advisors held its Royalty Pharma (RPRX) position steady in Q1 2026 at 10,493 shares worth $503K. The position accounts for 0.03% of the portfolio, ranked #375.

Frank Rimerman Advisors first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Frank Rimerman Advisors held 10,493 shares of Royalty Pharma worth $503K as of Q1 2026.
Frank Rimerman Advisors left its Royalty Pharma share count unchanged in Q1 2026.
Royalty Pharma made up 0.03% of Frank Rimerman Advisors's portfolio in Q1 2026, its #375 holding.
Frank Rimerman Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.